Lactulose and combination therapy of hepatic encephalopathy: The role of the intestinal microflora

Digestive Diseases

Volumn 14, Issue , 1996, Pages 53-63

  Weber, Fredrick L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Ammonia; Dietary fiber; Hepatic encephalopathy; Lactulose

Indexed keywords

AMMONIA; ANTIINFECTIVE AGENT; GASTROINTESTINAL AGENT; LACTULOSE; LAXATIVE; NEOMYCIN; NEUROTOXIN; NITROGEN; UREA;

BACTERIUM; BLOOD; CHEMISTRY; DIETARY FIBER; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FECES; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE; LIVER; METABOLISM; MICROBIOLOGY; REVIEW;

AMMONIA; ANTI-BACTERIAL AGENTS; BACTERIA; CATHARTICS; DIETARY FIBER; DRUG SYNERGISM; FECES; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; INTESTINES; LACTULOSE; LIVER; NEOMYCIN; NEUROTOXINS; NITROGEN; UREA;

EID: 2742579420     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000171583     Document Type: Article

References (71)

1. Weber FL Jr, Vcach GL: The importance of ihe small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77: 235-240.
2. Weber FL Jr, Friedman DW, Fres-sard KM: Ammonia production from intraluminal amino acids in canine jejunum. Am J Phvsiol 1988; 254:G264-G268.
3. Rudman D, Galambos JT, Smith RB III, Salam A, Warren WD: Comparison of the effect of various amino acids upon the blood ammonia concentration of patients with liver disease. Am J Clin Nutr 1973:26: 916-925.
4. Bessman AN, Mirick GS, Hawkins R: Blood ammonia levels following the ingestion of casein and whole blood. J Clin Invest 1958:37:900-998.
5. Van Berio CLH, van de Bogaard EJM, van der Heijden MAH, van Eijk HMH, Janssen MA, Bost MCF, Soeters PB: Is increased ammonia liberation after bleeding in the digestive tract the consequence of complete absence of isoleucine in hemoglobin? A study in pigs. Hepatology 1989:10:315-323.
6. Fenton JC, Knight EJ, Humpherson PL: Milk and cheese diet in portal-systemic encephalopathy. Lancet 1966;i: 164- 166.
7. Condon RE: Effect of dietary protein on symptoms and survival in dogs with an Eck fistula. Am J Surg 1971;121:107-114.
8. Weber FL Jr, Minco D, Fresard K, Banwell K: Effects of vegetable diets on nitrogen metabolism in cirrhotic subjects. Gastroenterology 1985:89: 538-544.
9. Greenbcrger NJ, Carley S, Schenker S, Bettinger I, Stamnes C, Beyer P: Effects of vegetable and animal protein diets in chronic hepatic encephalopathy. DigDis 1977:22:845-855.
10. Welch JD, Cassidy D, Prigantano GP, Gunn CG: Chronic hepatic encephalopathy treated with oral lactose in a patient with lactose malabsorption. N Engl J Med 1974:291: 240-241.
11. Uribe M: Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients. DigDis Sei 1980:25:924-928.
12. Soeters PB, van Leeuwcn PAM: Ammoniak und Glutaminstoffwechsel des Darms: Einfluss von Lactulose und Neomycin. Infus Ther 1986;13:186-190.
13. Ingelfinger F: Editorial comments; in Becson PB et al (eds): Year Book of Medicine. Chicago. Year Book Medical. 1964-1965, pp 591-592.
14. Birchcr J, Müller J, Guggenheim P, Haemmerli UP: Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966;i: 890-892.
15. Conn HO, Leevy CM, Vlaheevic ZR, Rodgers JB, Maddrey WC, Sceff L, Levy L.L: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology 1977; 72:573-583.
16. Conn H O, Floch M H: Effect s of lactulose and Lactobacillus acidophilus on the fecal flora. Am J Clin Nutr 1970;23:1588-1594.
17. Bircher J, Hacmmerli UP, Scollo-Lavizzari G, Hoffmann K: Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. Am J Med 1971:51:148-159.
18. Vince A, Zeegen R, Drinkwater JE, O'Grady F, Dawson AM: The effect of lactulose on the fccal flora of patients with hepatic encephalopathy. J Med Microbiol 1974:7:163-168.
19. Zeegan R, Drinkwater JE, Fenton JCB, Vince A, Dawson AM: Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy. Q J Med 1970:39:245-263.
20. Castell DO, Moore EW: Ammonia absorption from the human colon. The role of non-ionic diffusion. Gastroenterology 1971;60:33-42.
21. Down PF, Agostini L, Murison J, Wrong OM: The interrelations of fccal ammonia. pH and bicarbonate: Evidence of colonic absorption of ammonia by non-ionic diffusion. Clin Sci 1972:43:101-114.
22. Weber FL Jr: Effect of lactulose on urea and nitrogen metabolism in cirrhotic patients. Gastroenterology 1979:77:18-23.
23. Vince A, Killingslcy M, Wrong OM: Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 1978:74:544-549.
24. Orskov ER, Fraser C, Mason VC, Mann SO: Influence of starch digestion in the large intestine of sheep on caecal fermentation, caecal microflora and faecal nitrogen excretion. BrJ Nutr 1970:24:671-682.
25. Mason VC, Palmer R: The influence of bacterial activity in the alimentary canal of rats on faecal nitrogen excretion. Acta Agrie Scand 1973: 23:141-150.
26. Stephen AM, Cummings JH: Mechanism of action of dietary fiber in the human colon. Nature 1980:284: 283-284.
27. Paigen K, Williams B: Catabolite repression and other control mechanisms in carbohydrate utilization. Adv Microb Physiol 1970;4:251 - 324.
28. Vince AJ, Burridge SM: Ammonia production by intestinal bacteria: The effects of lactose, lactulose and glucose. J Med Microbiol 1980:13: 177-191.
29. Brown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM: Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemelry device. Gut 1974,15: 999-1004.
30. Mortcnsen PB, Holtug K, Bonnen H, Clausen MR: The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 1990:98:353-360.
31. Mortensen PB, Hove H, Clausen MR, Holtug K: Fermentation to short-chain fatty acids and lactate in human faecal batch cultures. Scand J Gastroenterol 1991;26:1285- 1294.
32. Vince AJ, McNeil NI, Wager JD, Wrong OM: The effect of lactulose, pectin, arabinoglactan, and cellulose on the production of organic acids and metabolism of ammonia by intestinal bacteria in a faecal incubation system. Br J Nutr 1990;63:17- 26.
33. Peters SB, Fisher A: Portal and peripheral blood short-chain fatty acid concentrations after caecal lactulose instillation at surgery. Gut 1992:33: 1249-1252.
34. Saunders DR, Wiggins HS: Conservation of mannitol. lactulose, and raffinose by the human colon. Am J Phyiol 1981;241:G397-G402.
35. Hammer MF, Fine RD, Santa Ana CA, Porter JL, Schiller LR, Fortran JS: Carbohydrate malabsorption. Its measurement and its contribution to diarrhea. J Clin Invest 1990:86: 1936-1944.
36. Mortensen PB: The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 1992;16:1350-1356.
37. Agnostini L, Down PF, Murison J, Wrong OM: Faecal ammonia and pH during lactulose administration in man: Comparison with other cathartics. Gut 1972:13:859-866.
38. Weber FL Jr, Banwell JG, Fresard KM, Cummings JH: Nitrogen in fecal bacterial, fiber, and soluble fractions of patients with cirrhosis: Effects of lactulose and lactulose plus neomycin. J Lab Clin Med 1987; 110:256-263.
39. Vince A, Dawson AM, Park N: Ammonia production by intestinal bacteria. Gut 1973;14:171-177.
40. Weber FL Jr, Fressard KM: Comparative effects of lactulose and magnesium sulfate on urea metabolism and nitrogen excretion in cirrhotic subjects. Gastroenterology 1981;80:994-998.
41. Bird SP, Hewitt D, Ratcliffc B, Gurr MI: Effects of lactulose and lactitol on protein digestion and metabolism in conventional and germ-free animal models: Relevance of the results to their use in the treatment of portosystemic encephalopathy. Gut 1990;31:1403-1406.
42. Shaw S, Werner TM, Lieber CS: Comparison of animal and vegetable protein sources in the dietary management of hepatic encephalopathy. Am J Clin Nutr 1983:38:59- 63.
43. DeBruijn KM, Blendis LM, Zilm DH, Carien PL, Anderson GH: Effect of dietary protein manipulations in subclinical portal systemic encephalopathy. Gut 1983:24:53- 60.
44. Uribe M, Márquez MA, Ramos GG, Ramos-Uribe MH, Vargas F, Villalobos A, Ramos C: Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets: A controlled crossover study. Dig Dis 1982;27:1109-1116.
45. Uribe M, Pibildox M, Malpica S, et al: Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mcllitus. Gastroenetcrology 1985; 88:901-907.
46. Weber FL Jr, Stephen AM, Kara-giannis EM: Effects of dietary fiber on nitrogen metabolism in cirrhotic patients. Gastroeneterology 1985; 88:1704.
47. Herrmann R, Shakoor T, Weber FL Jr: Beneficial effects of pectin in chronic hepatic encephalopathy. Gastroenterology 1987:92:1795.
48. Aminosharic ME, Weber FL Jr: Effects of dietary fiber and antibiotics on ammonium production in a fecal incubation system. Gastroenterology 1992; 102:A774.
49. Aminosharic ME, Weber FL Jr: Comparison of starch and lactulose, alone and in combination with antibiotics. on ammonium production in a fecal incubation system. Gastroenterology 1993;104:A859.
50. Dawson AM, McLaren J, Sherlock S: Neomycin in the treatment of hepatic coma. Lancet 1957;ii: 1262-1268.
51. Fisher CJ, Faloon WW: Blood ammonia levels in hepatic cirrhosis: Thcircontrol by the oral administration of neomycin. N Engl J Med 1957;256:1030-1035.
52. Macbeth WAAG, Kass E, McDermott WV Jr: Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 1965;i:399-403.
53. Morgan MH, Read AF, Speller DCE: Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7.
54. Attcrbury CE; Maddrey WC, Conn HO: Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trail. Am J Dig Dis 1978;23:398-406.
55. Phear EA, Rubner B, Sherlock S, et al: Methionine toxicity in liver disease and its prevention by Chlortetracycline. Clin Sei 1956; 15:93- 117.
56. Simon GL, Gorbach SL: Intestinal flora in health and disease. Gastroenterology 1984:86:174-193.
57. Parini P, Cippola A, Ronchi M, Sal-zetta A, Mazzella G, Roda E: Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992; 52:34-39.
58. Pcdretti G, Calzetti C, Missale C, Fiaccadori F: Rifaximin versus neomycin on hyperammonemia in chronic portal systemic of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175- 178.
59. Festi D, Mazzetta G, Orsini M, Sat-tili S, Sangermano A, LiBassi S, Pa-rini P, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E: Rifaximin in the treatment of chronic hepatic encephalopathy: Results of a multicenter study of efficacy and safety. CurrTherRes 1993;54:598-609.
60. Bucci L, Palmieri GC: Doubleblind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118.
61. Massa P, Vallcrino E, Dodcro M: Treatment of hepatic encephalopathy with rifaximin: Double-blind, double-dummy study versus lactulose. Eur J Clin Res 1993:4:7-18.
62. Giliis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal flora. Drugs 1995;49:467-484.
63. Sabath LD, Tuftegard I: Rapid microassays for clindamycin and gen-tamycin when present together and the effect of pH and of each other on the antibacterial activity of the other. Antimicrob Agents Chentother 1974;6:54-59.
64. Lcbck G, Luginbiihl M: Effects of lactulose and lactitol on human intestinal flora: in Conn HO. Bircher J (eds): Hepatic Encephalopathy; Syndromes and Therapies. Bloomington. Medi-Ed Press, 1994, pp 275-284.
65. Ristucia AM: Aminoglycosides; in Ristuccia AM, Cunha BA (eds): Antimicrobial Therapy. New York. Raven Press. 1984, pp 305-328.
66. Hancock RE: Aminoglycoside uptake and mode of action with special reference to streptomycin and genta-mycin. I. Antagonists and mutants. J Antimicrob Chentother 1981:8: 249-276.
67. Reed AE, McCarthy CF, Heaton KW: Lactobacillus acidophilus (En-pac) in treatment of hepatic encephalopathy. Br Med J 1966;i: 1267-1269.
68. Conn HO, Lieberthal MM: Lactulose and neomycin: Combined therapy; in The Hepatic Conta Syndromes and Lactulose. Baltimore, Williams & Wilkins, 1979, pp 340-345.
69. Weber FL Jr, Fresard KM, Lally BR: Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 1982:82: 213-217.
70. Patel DH, Wcstaby D, Mahida YR, Plamer KR, Rees R, Clark ML, Dawson AM, Silk DBA: Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy. Gut 1987:28:255- 259.
71. Imler M, Kurt Z, Bockel R: E’tude comparative du traitement de l’en-cephalopathie porto-cave par le lactulose. les bacilles lactiques et les antibiotiques. Thérapeutique 1971; 47:237-248.